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PROFBENCHIEANDDRATHENA—AMODERN
TRAGEDY…
…..in which Professor Benchie, an established super-sub-
speciality clinician who spends most of his time performing
laboratory research, profers advice toAthena, an enthusias-
tic early career physician who, although she spent summers
in the lab as a medical student, is just finishing a research fel-
lowship that included a course in clinical research and won-
ders whether she would prefer to devote her research time
to patient-based therapeutic trials.
HUBRIS
“So Prof Benchie, my hero”, asked Dr Athena, the seeker after
truth, “There are hundreds of diseases in this world which need
a cure, and with my three year fellowship I am just the person to
do it. Whither should I direct my research endeavours?”
“I still can’t tempt you to my laboratory? The clean white
bench, the precision scales, the control of every variable?
That’s where the future lies, not in messy research involving
human subjectswhodon’t take their tablets, andwhodefault
from followup, andwhere youneed thousands of patients to
say anything of substance.Why, I can show a drug improves
pain symptoms using only 6 animals”
“I know, I know, I’mreally jealous of the purity of the laboratory
but I’d really like to try doing research which helps people right
away. What about taking something that works in the lab, and
seeing whether it works in patients? That thing they call ‘transla-
tional medicine.’ So much has been written about it, there must
be well validated approaches to doing that kind of thing?”
“Well, here in the labwe tend not to get involved in that sort
of methodology. Our job is to show that the drug can work
in our model systems”
“That the drug can work?”
“Under the right circumstances, of course, with a model of
the correct severity, in experienced hands, when the moon
is in the correct phase and other heavenly bodies are
appropriately distributed”
“So, before I start my clinical trial to see whether this
drug does work, is there anything I should try to find out
about the bench research that nominated it; anything else
I should know?”
“Jeez, you’re asking me? You’re the one talking about
wanting to do clinical trials. I guess though that there are a
few things you could look out for. Firstly, do the in vivo data
come from a good lab?”
“How do I know if it’s a good lab? You mean that it does high
quality research at low risk of bias? Are there parallel standards to
those applied in clinical trials? Stuff like randomised animals,
blinded treatments and observations, pre-specified primary ana-
lyses, appropriate sample size calculations, and the reporting of
animals excluded from analyses?”
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“Look, don’t start with that mumbo-jumbo. You just know
their results are true because you know their work, and
have reviewed their papers and so you just know. None of
your fancy biases apply in the lab, because we can control
everything. All the animals are identical, and we measure
outcomes using machines which are not susceptible to bias.
If we lose an animal during an experiment we just add
another, and if you use the right statistical test on the right
subgroup you need hardly any animals”
“Ok, lets come back to that later, because I’m not sure I share
your confidence in bias-free bench research. What else?”
“Well, you’ll want to know that the findings have been
reported in another lab”
“Great. Is finding that confirmation straightforward? I mean, is
there something like clinicaltrials.gov, where I can find all the lab
experiments that have tested the drug, so I can see if they have
consistently positive findings?”
“I’m afraid not, but you could look in Pubmed. The trouble
(Professor Benchie shifts uneasily) is that some experiments
might never have been published. And, it’s possible that
these unpublished studies are the ones that concluded the
drugs don’t work—but since they never got published we
don’t know. You’ll just have to trust the research that did
get published”
“With all due respect, that’s crazy! Don’t you guys look for
publication bias and measure its impact? And don’t you look to
see whether there’s an outcome reporting bias by comparing,
published results with their respective study protocols?”.
“Protocols? You really don’t understand howbench research
works, do you?A publication should be a thing of rare beauty,
flawless in every respect.We might start off with a protocol,
butwe’ll end updoing something different.How that happens
isn’t important. Sowemight look at 4 or 5 differentmeasures
of outcome, and of course we’ll report the ones that show
significant effects. And we’ll use a range of statistical tests
according to what seems to fit the data best”
“Prof, now I’m really worried. I’m not sure, from what you’ve
said, that I can rely on conclusions that come out of the lab. Far
from being clean, and precise, you seem to be ignoring problems
with validity which, because they also bedevil clinical studies,
we’ve worked to prevent and overcome. Let me go and read
up about this ….”
With thisDrAthena goes off to the biomedical library and
does some literature research, helpfully guided by their staff
and an expanding number of relevant publications on this
issue ….
Later that same month ….
NEMESIS
…. OK, Prof Benchie, sit down and hear the news:-
1. First, it turns out that animal studies are just as vulner-
able to bias as clinical studies. Worse yet, lots of them
fail to avoid them. For example, non-randomised,
non-blinded lab studies were five times as likely to
report positive findings than randomised, blinded
studies. Moreover, the repeated inability of other
bench researchers to replicate these positive results
shows that lots of the former had to be false-positives.
Across models of neurological disease there is a per-
sistent overstatement of drug efficacy in studies that
do not take simple measures to reduce the risk
of bias.
2. A minority of animal studies—in neurological disease
and more broadly—report taking these simple mea-
sures to reduce the risk of bias. Finally, appearance
in journals with high impact factors carries no guaran-
tee that investigators have made even the most basic
efforts to reduce the risk of bias.
3. There’s a lot of publication bias about too, and
I couldn’t find any systematic efforts by the in vivo com-
munity to address this issue. The best estimate from
attempts to measure the scale of the problem is that
around 20% of bench studies remain unpublished,
and that translates to an overstatement of efficacy
by around one third.
4. The whole field of in vivo research doesn’t seem
to know what a power calculation is—and many
studies are underpowered for the effects they
purport to detect. In stroke research, for instance,
studies are powered at about 30%, so two-thirds
of research effort—including yours, Professor
Benchie—is likely to fail even if a pre-stated null
hypothesis is false.
5. Because study protocols and their statistical analysis
plans are not routinely available, we simply can’t tell
if either (1) theoutcomes and theirmeasures reported
are those that the investigator had decided a priori to
be the most important (rather than the result of look-
ing for the most statistically significant pony) one; or
(2) that the statistical test reported is the one specified
prior to the study, or simply the first one which gave a
p value of less than 0.05).i
6. In summary, my literature search documented that,
when bench scientists attempt to replicate the work
of their fellow bench scientists—for instance in drug
discovery work, or cancer, or motor neuron disease
models—they have not been able to replicate about
two-thirds of the positive findings originally reported.
Indeed, this is often the case when the drugs being
tested are nominated by robust systematic review
and meta-analysis.
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7. No wonder, then, that of 374 compounds alleged to
provide neuroprotection after stroke in animal mod-
els, only one generated positive evidence of efficacy in
human RCTs.
“Cripes, Athena. Your systematic demolition of our cher-
ished bench research methods has shaken my confidence
in my own work, and I need to go away and read and think
and reformulate my research strategies and tactics. I guess
you won’t be coming near the lab then”
CATHARSIS
“You know Benchie, I think I just might. Bench scientists are
clearly in need of some help, and your responsiveness to my
review suggests a receptivity to changes in the way you generate
the bench research input into translational medicine by
borrowing and employing the bias-reducing strategies and tactics
of RCTs. Collaborating in sorting that out could be both worthy
and lots of fun!”
“But what if—it pains me to even consider the possibility—
what if it’s all wrong, like the MND research, or the stroke
drugs? How will you know that there’s any prospect of
success?”
“We could replicate the approach of stroke trialists in your
lab—conducting large, adequately powered, proof of concept ani-
mal studies at low risk of bias, according to strict protocols with pre-
specified primary outcome measures and pre-specified statistical
analysis plans. Wemight even think about doing multicentre ani-
mal studies, with central randomisation and outcome assess-
ment, and monitoring to drive up standards and to detect fraud”.
“Fraud? Are you saying that you people fabricate data, too?”
Box 1. What Athena found out
• In 2003, Bebarta et al. reported3 an analysis of abstracts submitted to the Society for Academic Emergency Med-
icine that described research using cell lines or animals. They found that 252 of 290 studies reported statistically
significant findings. 94 reported randomisation and only 31 reported blinding. Non randomised (odds ratio 3.4)
and non-blinded (odds ratio 3.2) studies were much more likely to report significant findings; and non-rando-
mised, non-blinded studieswere evenmore likely to report significant findings than the 10%of studieswhichwere
both randomised and, blinded studies (odds ratio 5.2).
• Dan Hackam looked at the fate of 76 interventions reported in highly cited publications in seven leading journals
which investigated a preventative or therapeutic intervention in an in vivo animal model.4 37%of studies had been
replicated in human randomised trials and 18% were contradicted by such studies; 45% remained untested in
humans.
• Despina Contopoulos-Ioannidis identified 101 articles published between 1979 and 1983 in high impact basic sci-
ence journals in which it was claimed that the technology studied had novel preventative or therapeutic potential.
By 2002 five drugs were licenced for clinical use, but only one had entered into common use for the licenced
indication.
• ToriO’Collins studied the fate of drugs developed for the treatment of ischaemic stroke;5 of 374 drugs which had
some reports of efficacy in animal models of focal cerebral iscahemia, only one—clot-busting treatment with
tPA—had successfully translated to human health.
• Just about every systematic review of animal data shows low levels of reporting of those study design features
which might reduce the risk of bias—across stroke,6–8 multiple sclerosis,9 Parkinson’s disease,10 glioma,11 myo-
cardial ischaemia,12 spinal cord injury,13 etc.…While reporting of randomisation and blinding in less than half of
studies, sample size calculations—how the size of the experiment was chosen—is reported in less than 1% of
studies. Initially this appeared to be a problem with the in vivo stroke literature, because that’s where this work
started—but in a random sample of in vivo and in vitro research in Pubmed randomisation was reported by only
14%, and the blinded assessment of outcome by only 2%.14
• ter et al. reported that most Dutch laboratory animal researchers considered publication bias to be a substantial
problem, and estimated that around 50% of studies remained unpublished.15
• Using data from in vivo strokemodelling Sena et al. used standard statistical approaches to suggest that aroundone
in six studies remained unpublished, leading to an overstatement of treatment efficacy of around 30%.16
• Tsilidis et al. studied the distributionof p values reported in 4445 in vivo experiments testing drug efficacy in animal
models of neurological disease.17 They found a gross excess of statistically significant findings (1719, compared
with an expected 919 positive studies), suggesting that, even once publication bias had been taken in to account,
the outcomes from many thousands of individual experiments had not been reported—that is that there was
selective outcome reporting bias.
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“Some people do.1 I’d like to think this is a very small propor-
tion of the research community, although it can be difficult to
detect so may be more prevalent. Central statistical monitoring
in a multicentre study is what led to detection of fraud in the Dar-
see case,2 and detailed in-house review of raw data is what
detected fraud in the Eaton case, where a scientist ended up
in prison for falsifying data (http://www.bbc.co.uk/news/uk-
scotland-edinburgh-east-fife-22186220).
“I hope that is uncommon—I’ve never directly observed it in
my colleagues”
“Indeed. The overwhelming majority of scientists—in the
lab or the clinic—want to do research of the highest quality.
It’s just that over the years, these efforts have been subverted
through worship of the false Gods ‘grants in’ and ‘papers out’.
As it turns out, neither of these are good measures of research
quality”
“So what should we do?”
“Well Prof. Benchie, I can’t sort this out by myself, and I don’t
think you can sort it out by yourself either. But together, learning
from the strengths and weaknesses of our respective back-
grounds, we should be able to make things a little better, a little
bit more reliable, to make the process of translation a little bit
more systematic. And as we revel in the camaraderie and enjoy-
ment of accumulating lots of little bits of improvement, we might
end up with quite a lot of improvement”
“That, Athena, sounds like the starting point for an exciting
journey. Do you mind if I join you?”
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ENDNOTE
i. “Looking for the pony” comes from a Christmas tale of two
brothers, one of whom was incurable pessimist and the other,
an incurable optimist. On Christmas day, the pessimist was
given a roomful of shiny toys and the optimist, a roomful of
horseshit. The pessimist opened the door to his roomful of toys,
sighed, and lamented, “A lot of these are motor driven and
their batteries will run down; and I suppose I’ll have to show
them to my cousins, who’ll break some and steal others; and
their paint will chip; and they’ll wear out. All in all, I wish you
hadn’t given me this roomful of toys.” The optimist opened
the door to his roomful of horseshit and, with a whoop of glee,
threw himself into the muck, and began burrowing through it.
When his horrified parents extracted his from the excrement
and asked him why on earth he was thrashing about in it, he
joyfully cried: ”With all this horse shit, there’s got to be a pony
in here somewhere!”
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